Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Capsaicin→

Capsaicin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
404-86-4
Molecular formula
C18H27NO3
Molecular weight
305.4 g/mol
Drug class
Transient receptor potential vanilloid 1 (TRPV1) agonisttopical analgesic
Mechanism of action
Initially activates TRPV1 receptors on peripheral nociceptive neurons, causing local warmth or burning. Repeated exposure leads to functional desensitisation and reduced release of pain-related neuropeptides, lowering peripheral nociceptive signalling.
Indications / reported uses
  • Topical relief of neuropathic pain, including postherpetic neuralgia and painful diabetic peripheral neuropathy, using the product-specific strength
  • Temporary relief of minor muscle and joint pain with lower-strength topical preparations; high-concentration patches require supervised application

Sources: US DailyMed — Capsaicin topical products · US FDA prescribing information — QUTENZA · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Capsaicin Environmental Risk Assessment (ERA) (the Capsaicin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.